

BMJ Open White rice, brown rice and the risk of type 2 diabetes: a systematic review and meta-analysis

Jiayue Yu,¹ Bhavadharini Balaji,² Maria Tinajero,³ Sarah Jarvis,³ Tauseef Khan,³ Sudha Vasudevan,⁴ Viren Ranawana,⁵ Amudha Poobalan,⁶ Shilpa Bhupathiraju,^{7,8} Qi Sun,⁸ Walter Willett,⁸ Frank B Hu,⁸ David J A Jenkins ^{3,9}, Viswanathan Mohan,¹⁰ Vasanti S Malik ^{3,8}

To cite: Yu J, Balaji B, Tinajero M, *et al.* White rice, brown rice and the risk of type 2 diabetes: a systematic review and meta-analysis. *BMJ Open* 2022;**12**:e065426. doi:10.1136/bmjopen-2022-065426

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2022-065426>).

Received 03 June 2022
Accepted 05 August 2022



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Vasanti S Malik;
vasanti.malik@utoronto.ca

ABSTRACT

Objective Intake of white rice has been associated with elevated risk for type 2 diabetes (T2D), while studies on brown rice are conflicting. To inform dietary guidance, we synthesised the evidence on white rice and brown rice with T2D risk.

Design Systematic review and meta-analysis.

Data sources PubMed, EMBASE and Cochrane databases were searched through November 2021.

Eligibility criteria Prospective cohort studies of white and brown rice intake on T2D risk (≥ 1 year), and randomised controlled trials (RCTs) comparing brown rice with white rice on cardiometabolic risk factors (≥ 2 weeks).

Data extraction and synthesis Data were extracted by the primary reviewer and two additional reviewers. Meta-analyses were conducted using random-effects models and reporting followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Risk of bias was assessed using the Newcastle Ottawa Scale for prospective cohort studies and the Cochrane Risk of Bias Tool for RCTs. Strength of the meta-evidence was assessed using NutriGrade.

Results Nineteen articles were included: 8 cohort studies providing 18 estimates (white rice: 15 estimates, 25 956 cases, $n=577\,426$; brown rice: 3 estimates, 10 507 cases, $n=197\,228$) and 11 RCTs ($n=1034$). In cohort studies, white rice was associated with higher risk of T2D (pooled RR, 1.16; 95% CI: 1.02 to 1.32) comparing extreme categories. At intakes above ~ 300 g/day, a dose-response was observed (each 158 g/day serving was associated with 13% (11%–15%) higher risk of T2D). Intake of brown rice was associated with lower risk of T2D (pooled RR, 0.89; 95% CI: 0.81 to 0.97) comparing extreme categories. Each 50 g/day serving of brown rice was associated with 13% (6%–20%) lower risk of T2D. Cohort studies were considered to be of good or fair quality. RCTs showed an increase in high-density lipoprotein-cholesterol (0.06 mmol/L; 0.00 to 0.11 mmol/L) in the brown compared with white rice group. No other significant differences in risk factors were observed. The majority of RCTs were found to have some concern for risk of bias. Overall strength of the meta-evidence was moderate for cohort studies and moderate and low for RCTs.

Conclusion Intake of white rice was associated with higher risk of T2D, while intake of brown rice was associated with lower risk. Findings from substitution trials on cardiometabolic risk factors were inconsistent.

STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ This systematic review and meta-analysis on rice intake and risk of type 2 diabetes (T2D) is the most comprehensive evidence synthesis to date that includes findings from both prospective cohort studies of hard endpoints and trials of intermediate cardiometabolic risk factors.
- ⇒ Key strengths include the large sample size and long duration of follow-up of cohort studies from different parts of the world, use of systematic methods including risk of bias and evidence grading specific for nutrition research, categorical and dose-response analyses and a number of sensitivity analyses to assess the robustness of the results.
- ⇒ Only three cohorts with data on brown rice were included in the meta-analysis, all of which were conducted among US health professionals, which limits the generalisability of the findings.
- ⇒ The overall strength of the meta-evidence from cohort studies was considered moderate and moderate and low for randomised controlled trials, thus the assessment of rice intake on T2D risk relies on observational studies and trials of limited quality on intermediate risk factors.

PROSPERO registration number CRD42020158466.

INTRODUCTION

The prevalence of type 2 diabetes (T2D) has continued to increase worldwide, especially in low-income and middle-income countries (LMICs),¹ where economic development and urbanisation are fuelling these trends.² Since rice is a staple food in many cultures and is predominant in most Asian diets, it is hypothesised that improving diet quality by replacing white rice with brown rice could play an important role in the prevention of T2D.³ White rice is a product of refining and polishing of the intact rice grain with the removal of the outer bran and germ layers, leaving the starchy endosperm as the primary

component. In contrast, brown rice, an intact whole grain, retains the bran and germ along with the fibre, vitamins and minerals contained in these layers of the grain. Dietary fibre and certain micronutrients such as magnesium found in the intact rice grain have been independently associated with lower risk of T2D.⁴ Brown rice also tends to have a lower glycaemic index (GI) compared with white rice, due to a higher fibre content and slower rate of absorption, although variability in GI exists across rice strains.^{5 6}

Epidemiological studies have linked intake of refined grains, including white rice, to a higher risk of T2D, while intake of whole grains, such as brown rice, has been linked to lower risk.⁷⁻⁹ Previous meta-analyses of cohort studies have shown positive associations between white rice intake and the risk of T2D particularly in Asian populations.^{10 11} Since these publications, a number of new studies have been published, providing data from additional world regions. In contrast to cohort studies, findings from randomised controlled trials (RCTs) comparing white rice with brown rice have been inconsistent. Two recent meta-analyses of RCTs found a benefit of brown rice compared with white rice on body weight but discrepant results on waist circumference and lipid parameters.^{12 13} However, these meta-analyses combined studies conducted among participants with and without T2D, which may have differential effects on macronutrient metabolism. To provide a current synthesis of the evidence, we conducted an updated systematic review and meta-analysis of cohort studies that examined intake of white rice and risk of T2D including a dose-response analysis. We also conducted separate meta-analyses on cohort studies of brown rice and risk of T2D and on RCTs that compared effects of brown rice and white rice on intermediate cardiometabolic risk factors among participants without T2D, in order to provide a comprehensive assessment of rice consumption and T2D risk.

METHODS

Patient and public involvement

No patient involved.

Literature search

To assess the relationship between rice intake and the risk of T2D, we conducted three a priori separate meta-analyses: (1) prospective cohort studies of white rice intake and risk of T2D; (2) prospective cohort studies of brown rice intake and risk of T2D and (3) RCTs comparing effects of brown rice and white rice intakes on risk factors for T2D. Relevant articles were identified by searching electronic databases PubMed, EMBASE and the Cochrane library from their respective index dates to November 2021. The search strategy incorporated Medical Subject Headings, and Title/Abstract (tiab) terms for all three databases with search/key terms related to rice and risk of T2D and T2D risk factors or biomarkers (online supplemental table 1). Additional

articles were identified from reference lists of included studies and relevant reviews.

Study selection

Studies were considered for inclusion in our meta-analysis based on the following criteria: (1) prospective cohort studies with at least 1 year of follow-up or RCTs with at least 2 weeks of intervention among healthy human participants aged ≥ 18 years without a diagnosis of T2D at baseline; (2) specified brown rice or white rice (or polished rice) intake as the exposure in cohort studies or comparison of brown rice versus white rice as the intervention in RCTs; (3) reported multivariable-adjusted relative risks (RR) with 95% CI for the association between white or brown rice intake and risk of T2D from cohort studies or the difference in changes of at least one biomarker of cardiometabolic risk (fasting blood glucose (FBG), HbA1c, HOMA-IR, triglycerides, total cholesterol, low-density lipoprotein (LDL)-cholesterol, high-density lipoprotein (HDL)-cholesterol, waist circumference, systolic blood pressure and diastolic blood pressure) between intervention and control groups from RCTs. We excluded articles that were not original research (ie, reviews, letters, conference proceedings or commentaries) or studies that combined rice intake with other dietary factors or lifestyle factor as a composite exposure. We did not consider case-control, cross-sectional or ecologic studies or the grey literature for inclusion or studies that were conducted in animal models. No language restrictions were applied. Titles and abstracts of identified studies were screened by the primary reviewer (JY), and potentially relevant articles were selected for full-text review, which was performed independently by the primary reviewer and two additional reviewers (SJ and MT). Any discrepancies were resolved through discussion with an additional author (VSM).

Data extraction

For each article identified, we extracted information on the following: study characteristics (authors, publication year, type of study, region/country, number of participants and duration); participant characteristics (sex, age, baseline weight/health status); type of rice consumed; quantity of rice consumed (g/d); cooking method; type of dietary assessment (eg, Food Frequency Questionnaires, 24-hour diet recall); RCT design (crossover, parallel and cluster); intervention and control modality and analysis strategy (statistical models and covariates). For prospective cohort studies, we extracted multivariable adjusted RRs and 95% CIs and confounder information. For RCTs, we extracted means and SEs of between-group difference in biomarkers of cardiometabolic risk (FBG, HbA1c, HOMA-IR, triglycerides, total cholesterol, LDL-cholesterol, HDL cholesterol, waist circumference, systolic blood pressure and diastolic blood pressure) from baseline to the end of follow-up. If a trial did not report the SE for the measurement of change, we imputed this value by using the correlation coefficient method referenced in

the Cochrane Handbook for Systematic Reviews of Interventions.¹⁴ For the trial by Ren *et al*,¹⁵ which reported on four different brown rice interventions with different rice drying processes, we extracted data for the comparison of standard brown rice with polished white rice, which is most consistent with the other studies in this meta-analysis.

Data synthesis and analysis

Random-effects models were used to provide summary estimates for all analyses, however fixed-effects models were also calculated, which is the preferred method when fewer than five estimates are available for analysis.¹⁶ For meta-analyses of prospective cohort studies of white rice and brown rice, the summary RRs were estimated along with corresponding 95% CIs, comparing extreme categories of intake. For RCTs, the mean between-group difference in biomarkers of T2D risk with SE was estimated with the brown rice group considered as the intervention and white rice group, the control. The I^2 statistic and Q -statistic with a corresponding p -value were used to assess heterogeneity between the included studies. In general, an I^2 value below 30% represented low heterogeneity; between 30% and 60% represented moderate heterogeneity and greater than 70% represented significant heterogeneity.¹⁴ To further explore potential sources of heterogeneity among cohort studies, meta-regression and subgroup analyses by sex, age, duration of follow-up, geographic region and adjustment for diet quality (as defined in individual studies as adjustment for key dietary factors or diet quality score) were conducted. The subgroups for geographic region were consistent with those reported in the Prospective Urban Rural Epidemiology (PURE) study, published by Bhavadarini *et al*,¹⁷ as follows: China, South Asia (India, Pakistan and Bangladesh) and the rest of the world. The study by Seah *et al* which included Chinese adults in Singapore was included with studies in China.¹⁸ We also conducted an additional subgroup analysis according to whether rice is typically consumed as a staple food in a given country. To assess the influence of individual cohort studies on the results, we conducted sensitivity analysis by systematically omitting one study at a time and recalculating the summary estimate. Fixed-effects cubic spline models were used to assess the dose–response for cohort studies evaluating white rice intake (per 1 serving, ie, 158 g increment) and fixed-effects fractional polynomial models were used to assess the dose–response for brown rice intake (per 50 g increment), given the smaller sample size and lower intake level across studies. A serving size of 50 g/d for brown rice was used to reflect real-world intake levels. For studies that did not report person-years, these values were calculated by multiplying the number of participants in each category by years of follow-up. For the study by Hodge *et al*,¹⁹ which did not report the number of cases per category, these were calculated using the reported RR and the following formula $\frac{100 \times RR}{\text{sum of } 100 \times RR} \times \text{total cases}$.²⁰ In this study, since the number of participants per category

was not reported, person years were calculated by taking the total number of person-years divided by four as the dose category was reported in quartiles.

The assessment of individual study quality was done using the Newcastle Ottawa Scale (NOS) for prospective cohort studies and the Cochrane Risk of Bias Tool for randomised trials (RoB-2) for RCTs. The overall strength of our meta-analysis was assessed using the NutriGrade scoring system, which was specifically designed to assess meta-evidence in nutrition research.²¹ NutriGrade is based on seven criteria (eight criteria for cohorts) with an overall score ranging from 0 to 10: risk of bias, precision, heterogeneity, directness, publication bias, funding bias and study design (for RCTs), effect size and dose–response (for cohorts). An overall score below four denotes evidence of very low quality. Scores of 4–5.99 and 6–7.99 denote low and moderate quality evidence, respectively. A score of 8 or higher denotes high quality meta-evidence. For meta-evidence from RCTs, we applied NutriGrade to outcomes that were measured in all included studies. Visual inspection of Funnel plots and Begg's and Egger's tests were used to assess potential publication bias. All analyses were performed using Stata V.16.0 (StataCorp).

RESULTS

Literature search

Our literature search yielded 9258 articles, with 3098 from PubMed, 4390 from EMBASE, 1770 from Cochrane and 7 external sources (figure 1). After removing duplicates, the remaining 4421 articles were screened according to our inclusion criteria, resulting in 109 articles for full-text review. We further excluded 4 duplicates, 6 reviews, 3 letters, 70 articles that did not meet our inclusion criteria (ineligible study design, intervention/comparator, population or outcome) and 7 articles without a full-text source (ie, conference abstracts). After final exclusions, 19 original articles were included in our meta-analysis, 8 of which were prospective cohort studies^{8 17–19 22–25} and 11 RCTs.^{15 26–35} For cohort studies that reported sex-specific estimates, the individual estimates were considered separately in the meta-analysis, yielding a total of 18 estimates (15 for white rice and 3 for brown rice) for inclusion in the meta-analysis.

Study characteristics

Characteristics of the prospective cohort studies of white rice and brown rice included in the meta-analysis are shown in table 1.

Studies represented multiple geographic regions including China, South Asia, the Middle East, Europe, Australia and the USA. There was a total of 577 426 participants from eight prospective cohort studies (providing 15 estimates) of white rice intake with a mean duration of 8.8 years (1–22 years), during which, 25 956 cases of T2D were reported. The 3 cohorts of brown rice intake included 197 228 participants with 14–22 years of follow-up and 10 507 cases of T2D from one study of US health




Figure 1 Literature search and study selection. RCTs, randomised controlled trials.

professionals.⁸ For all studies, participants ranged in age from 18 to 87 years, the majority of whom were women. Food Frequency Questionnaires (FFQs) were used exclusively for dietary assessment and most of the cohort studies were considered to be of good or fair quality with a NOS score above 5, except for studies by Nanri *et al*²³ and Soriguer *et al*,²⁴ which were considered poor quality due to downgrades for high attrition, poor comparability and inadequate control for confounding. Key covariates, such as age, sex, body mass index, physical activity and total energy intake, were adjusted in all studies, except for the study by Soriguer *et al*, which adjusted for age, sex, glucose metabolism and carbohydrate intake²⁴ (online supplemental table 2). Characteristics of RCTs included in the meta-analysis are shown in table 2.

There was a total of 1034 participants and intervention periods ranged from 1 month (4 weeks) to 24 months (104 weeks). Studies by Kazemzadeh *et al*²⁸ and Malik *et al*³⁰ used a crossover design with a 2-week washout period and the study by Shimabukuro *et al*³⁴ used a crossover design with no washout, while the other studies were parallel trials. Eight studies specified the type of rice or processing method used in the intervention.^{15 29–33} Araki

et al used partially abraded brown rice (PABR) compared with white rice²⁹ and Malik *et al* used parboiled brown rice compared with non-parboiled white rice of the same strain (BPT5204).³⁰ Geng *et al*,³² Mai *et al*³¹ and Bui *et al*³⁵ used pregerminated brown rice as the intervention compared with white rice. Kuroda *et al* used ultra-high hydrostatic pressurising brown rice compared with white rice³³ and Ren *et al* and Shimabukuro *et al* used the Japonica cultivar (Suijing 18 paddy rice) with the husk removed compared with polished white rice of the same strain.^{15 34} Studies by Ren *et al*¹⁵ and Bui *et al*³⁵ were considered to have a high risk of bias, while studies by Zhang *et al*²⁶ and by Mai *et al*³¹ were considered to have a low risk of bias. The remaining studies were found to have some concern for risk of bias, primarily due to the randomisation process and intended intervention. Details of the outcomes from the RCTs are shown in online supplemental table 3.

White rice intake and risk of type 2 diabetes

As shown in figure 2, intake of white rice was associated with higher risk of T2D, with a pooled RR of 1.16 (1.02–1.32) comparing extreme categories. Significant heterogeneity was observed among the estimates, with an I² value of

Table 1 Characteristics of prospective cohort studies of white rice and brown rice intake and risk of type 2 diabetes (T2D)

Author	Location and study population	Participants (n, sex, age)	Cases	Duration (years)	Outcome assessment	Newcastle-Ottawa Scale*
White rice						
Hodge <i>et al</i> 2004 ¹⁹	Australia. Melbourne Collaborative Cohort Study (MCCS)	31 641; mixed; aged 40–69 years	365	4	Self-reported, confirmed by clinician	Good (3★; 1★; 3★)
Villegas <i>et al</i> 2007 ²²	China. Shanghai Women's Health Study (SWHS)	64 227; female; aged 40–70 years	1608	4.6	Self-reported	Good (3★; 2★; 2★)
Nanri <i>et al</i> 2010 ²³	Japan. Japan Public Health Center-based Prospective Study (JPHC)	25 666; male; aged 40–69 years	625	5	Self-reported, confirmed by medical records	Poor (3★; 2★; 1★)
Nanri <i>et al</i> 2010 ²³	Japan. Japan Public Health Center-based Prospective Study (JPHC)	33 622; female; aged 40–69 years	478	5	Same as above	Poor (3★; 2★; 1★)
Sun <i>et al</i> 2010 ⁸	USA. Health Professionals Follow-up Study (HPFS)	39 765; male; aged 32–87 years	2648	20	Self-reported, confirmed by questionnaire	Fair (2★; 1★; 2★)
Sun <i>et al</i> 2010 ⁸	USA. Nurses' Health Study (NHS)	69 120; female; aged 37–65 years	5500	22	Same as above	Fair (2★; 2★; 2★)
Sun <i>et al</i> 2010 ⁸	USA. Nurses' Health Study II (NHS II)	88 343; female aged 26–45 years	2359	14	Same as above	Fair (2★; 2★; 2★)
Soriguer <i>et al</i> 2013 ²⁴	Spain. Pizarra Study (PS)	605; mixed; aged 18–65 years	54	6	Identified via fasting blood glucose and OGTT	Poor (3★; 0★; 2★)
Golozar <i>et al</i> 2017 ²⁵	Iran. Golestan Cohort Study (GCS)	4754; female; aged 40–87 years	902†	1–5	Identified via fasting blood glucose or medication use	Good (3★; 2★; 2★)
Golozar <i>et al</i> 2017 ²⁵	Iran. Golestan Cohort Study (GCS)	4475; male; aged 40–87 years	902†	1–5	Same as above	Good (3★; 2★; 2★)
Golozar <i>et al</i> 2017 ²⁵	Iran. Tehran Lipid and Glucose Study (TLGS)	1197; female; aged ≥20 years	81†	1–5	Identified via fasting blood glucose or OGTT or medication use	Good (3★; 2★; 2★)
Golozar <i>et al</i> 2017 ²⁵	Iran. Tehran Lipid and Glucose Study (TLGS)	976; male; aged ≥20 years	81†	1–5	Same as above	Good (3★; 2★; 2★)
Seah 2018	Chinese living in Singapore. Singapore Chinese Health Study (SCHS)	35 298; female; aged 45–74 years	3012	11	Self-reported, confirmed by follow-up interview and medical assessments	Fair (2★; 1★; 3★)
Seah 2018	Chinese living in Singapore. Singapore Chinese Health Study (SCHS)	45 411; male; aged 45–74 years	2195	11	Same as above	Fair (2★; 1★; 3★)
Bhavadarini <i>et al</i> 2020 ¹⁷	21 countries. Prospective Urban Rural Epidemiology Study (PURE)	132 373; mixed; aged 35–70 years	6129	9.5	Self-reported with >90% confirmed by medical record and/or blood test	Good (3★; 2★; 3★)
Brown rice						
Sun <i>et al</i> 2010 ⁸	USA. Health Professionals Follow-up Study (HPFS)	39 765; male; aged 32–87 years	2648	20	Self-reported, confirmed by supplementary questionnaire	Fair (2★; 2★; 3★)
Sun <i>et al</i> 2010 ⁸	Nurses' Health Study (NHS)	69 120; female; aged 37–65 years	5500	22	Same as above	Fair (2★; 2★; 3★)
Sun <i>et al</i> 2010 ⁸	Nurses' Health Study II (NHS II)	88 343; female; aged 26–45 years	2359	14	Same as above	Fair (2★; 2★; 3★)

Good = (3/4★; 1/2★; 2/3★); fair = (2★; 1/2★; 2/3★); poor = 0/1★ for selection; OR 0★ for comparability; OR 0/1★ for outcome/exposure.
 *Newcastle-Ottawa Scale: the star scores (★) are arranged in the order of selection, comparability and outcome/exposure domains.
 †Number of cases by sex was not specified, and the reported numbers are the total number of the cases across both sexes.
 OGTT, oral glucose tolerance test.

73%. The fixed-effects model was similar, with a pooled RR of 1.13 (1.06–1.20). Stratified analysis by sex, age, follow-up period, adjustment for diet quality, geographic region and regional rice consumption habits showed some differences in estimates across subgroups (online supplemental figures 1–6). However, none of the differences across subgroups were statistically significant. I^2 values were not materially different in overall estimates compared with stratified results suggesting other potential sources of heterogeneity.

Brown rice intake and risk of type 2 diabetes

We observed an inverse association between intake of brown rice and the risk of T2D, with a pooled RR of

0.89 (0.81–0.97) comparing extreme categories with an I^2 value of 0% (figure 3). Results from the fixed-effects model were identical.

Dose–response analysis

The fixed-effects cubic spline for intake of white rice in relation to risk of T2D showed a non-linear relationship between intake of white rice and risk of T2D (p-value for non-linearity < 0.001) at consumption levels below ~300 g/d (cooked weight) (figure 4). At intakes above this threshold, each one serving (158 g cooked weight) increment in white rice intake was associated with a 13% higher risk of T2D (RR: 1.13; 95% CI: 1.11 to 1.15,

Table 2 Characteristics of RCTs replacing white rice with brown rice on type 2 diabetes (T2D) risk factors

Author	Design	Participants (location, n, % female, age, health status)	Duration (weeks)	Intervention diet	Control diet	Cooking method	Amount consumed	Dietary assessment for adherence	RoB-2*
Zhang <i>et al</i> 2011 ²⁶	Parallel	Shanghai, China: n=202; %female=47; mean age ~50 year; MetS	16	Cooked BR packed for 225 g/day from Monday to Saturday (n=101)	Cooked WR packed for 225 g/day from Monday to Saturday (n=101)	Steamed under 0.3 MPa for ~75 min, with R:W ratios† of 1:1 for WR and 1:1.25 for BR (#BR soaked for at least 1 hour before cooking)	Ad libitum, and allowed to consume with other staple foods on Sundays	3-day food record	Low risk
Wang <i>et al</i> 2013 ²⁷	Parallel	Chinese American: n=57; %female=38; prediabetic	12	BR (n=28)	WR (n=29)	Boiled in water for 30 min	Ad libitum based on usual intake	3-day food record	Some concern
Kazemzadeh <i>et al</i> 2014 ²⁸	Cross-over	Iran: n=40; %female=100; aged 18–50 year; healthy	6	150 g/day cooked BR (n=20)	150 g/day cooked WR (n=20)	Raw rice packaged and provided to participants to prepare at home	150 g/day cooked rice	3-day food record	Some concern
Bui <i>et al</i> 2014 ³⁵	Parallel	Vietnam: n=60; %female=100; aged 45–65 year; IGT	16	540 g/day PGBR (n=30)	540 g/day WR (n=30)	Not specified	540 g/day with normal activities of daily life without restriction	24-hour diet recall	High risk
Shimabukuro <i>et al</i> 2014 ³⁴	Cross-over	Japan: n=27; %female=0; age 41 year; MetS	8	150 g/day BR (n=14)	150 g/day WR (n=13)	Not specified	150 g/day with regular dietary intake/exercise habits	Self-recorded compliance	Some concern
Geng <i>et al</i> 2016 ³²	Parallel	Wuxi, China: n=191; %female=49.74; aged 40–70 year; dyslipidaemia	12	150 g/day cooked PGBR (n=94; female=49)	150 g/day cooked WR (n=97; female=47)	Processed and prepared by patent agent	150 g/day without change in dietary habits and lifestyle	Semi-Quantitative Food Frequency Questionnaire (SQFFQ) carried by trained staff	Some concern
Araki <i>et al</i> 2017 ²⁹	Parallel	Japan: n=41; %female=53.7; aged 40–64 year; prediabetic	12	200 g cooked PABR twice a day (n=20; female=10)	200 g cooked WR twice a day (n=21; female=12)	Steamed under cooking mode for WR, with R:W ratios of 1:1 for WR and 1:2 for PABR	400 g/day with additional ad libitum consumption of staple foods for one daily meal	Brief self-administered Diet History Questionnaire (BDHQ) confirmed by dietician	Some concern
Malik <i>et al</i> 2019 ³⁰	Cross-over	Chennai, India: n=166; %female=45; aged 25–65 year; overweight	12	Parboiled BR (strain: BPT5204)(n=85)	Non-parboiled WR (strain: BPT5204) (n=81)	Prepared by trained dietitians, and pressure cooked with R:W ratios of 1:2.5 for WR and 1:2 for BR	Two ad libitum meals/day	Direct observation and 24-hour diet recall	Some concern
Kuroda <i>et al</i> 2019 ³³	Parallel	Japan: n=52; %female=51.9; aged ≥65 year; healthy	104	100 g/day UHPBR (n=27)	100 g/day WR (n=25)	Supplied from the company	100 g/day cooked rice	A general questionnaire on lifestyle, and BDHQ	Some concern
Mai <i>et al</i> 2020 ³¹	Parallel	Vietnam: n=80; %female=80; aged 55–70 year; MetS	13	200 g/day PGBR (n=40; female=36)	200 g/day WR (n=40; female=36)	Packaged in a 2 kg capsule per day	200 g/day for 10 days each time without changes in lifestyle and medicine taking	SQFFQ	Low risk
Ren <i>et al</i> 2020 ¹⁵	Parallel	China: n=112; %female=44.6; aged 18–70 year; MetS	4	Cooked BR (n=28)	Cooked polished rice (n=28)	Washed and soaked in clear water with R:W ratio of 1:1.35 for 30 min. Then cooked in an electric cooker for 30 min and kept at temperature for 10 min	100 g rice (50 g sample rice and 50 g polished rice), coupled with 30 g sauced beef, 150 g salad and 50 g eggs	Not specified	High risk

*RoB-2=risk of bias 2.0.

†R:W ratio=rice-to-water ratio (in weight).

‡Conversion from uncooked rice to cooked rice by multiplying 2.5.

BR, brown rice; IGT, impaired glucose tolerance; MetS, metabolic syndrome; n, number of participants; PABR, partially abraded brown rice; PGBR, pregerminated brown rice; RCTs, randomised controlled trials; UHPBR, ultra-high hydrostatic pressurising brown rice; WR, white rice.




Figure 2 Forest-plot of white rice consumption and risk of type 2 diabetes (T2D). Risk of T2D (RR and 95% CI) comparing extreme categories of white rice intake from prospective cohort studies. Horizontal lines denote 95% CIs; solid squares represent the point estimate of each study with the size proportional to study weight. Open diamonds represent pooled estimates from the random-effects model (DerSimonian-Laird) and fixed-effects model based on 15 cohort studies (n=5 77 426). Study weights are from the random-effects analysis. The I^2 and p values for heterogeneity are shown. The red vertical line represents unity. F, female; GCS, Golestan Cohort Study; HPFS, Health Professionals Follow-up Study; JPHC, Japan Public Health Center-based Prospective Study; M, male; MCC, Melbourne Collaborative Cohort Study; NHS, Nurses' Health Study; PS, Pizarra Study; PURE, Prospective Urban Rural Epidemiology Study; SCHS, Singapore Chinese Health Study; SWHS, Shanghai Women's Health Study; TLGS, Tehran Lipid and Glucose Study.

p value for linearity, <0.001). In subgroup analysis, a similar threshold was observed among studies that were not conducted in China or South Asia (rest of the world) while a j-shaped association was observed in studies that were conducted in China, and a linear dose-response

was observed in studies that were conducted in South Asia (online supplemental figure 7). When stratified by regional rice consumption habits, a j-shaped association was observed in countries that typically consume rice as a staple, likely driven by studies from China, while a linear




Figure 3 Forest-plot of brown rice consumption and risk of type 2 diabetes (T2D). Risk of T2D (RR and 95% CI) comparing extreme categories of brown rice intake from prospective cohort studies. Horizontal lines denote 95% CIs; solid squares represent the point estimate of each study with the size proportional to study weight. Open diamonds represent pooled estimates from the random-effects model (DerSimonian-Laird) and fixed-effects model based on three cohort studies (n=197 228). Study weights are from the random-effects analysis. The I^2 and p values for heterogeneity are shown. The red vertical line represents unity. HPFS, Health Professionals Follow-up Study; NHS, Nurses' Health Study.




Figure 4 Dose–response meta-analysis of white rice consumption and risk of type 2 diabetes (T2D). Fixed-effects cubic spline for intake of white rice in relation to risk of T2D. Black solid line represents the point estimates and the black dashed lines represent the corresponding 95% CI's. The red solid line indicates the exact linear relationship and red dashed line represents unity. A departure from linearity was observed at intake levels below ~300 g/d (cooked weight) (p value for non-linearity <0.001). RR at 1 serv/d (158 g): 0.97; 95% CI: 0.92 to 1.02. A linear dose–response was observed at intake levels above 300 g/day with each serving/day (158 g) increment associated with a 13% higher risk of T2D (RR: 1.13; 95% CI: 1.11 to 1.15, p value for linearity, <0.001).

dose–response was observed in countries that do not typically consume rice as a staple and the rest of the world (online supplemental figure 8).

The non-linear polynomial model for intake of brown rice showed no evidence of non-linearity between brown rice consumption and risk of T2D (p-value for




Figure 5 Dose–response meta-analysis of brown rice consumption and risk of type 2 diabetes (T2D). Non-linear polynomial model for intake of brown rice in relation to risk of T2D. Black solid line represents the point estimates and the black dashed lines the corresponding 95% CIs. The red solid line indicates the exact linear relationship and the red dashed line represents unity. No departure from linearity was observed (p value for non-linearity, 0.13). RR at 50 g/d (cooked weight): 0.88; 95% CI: 0.82 to 0.95. A linear dose–response was observed with each 50 g/d increment associated with a 13% lower risk of T2D (RR: 0.87; 95% CI: 0.80 to 0.94, p value for linearity, 0.001).

Table 3 Pooled estimates for between-group difference in type 2 diabetes (T2D) risk factors from RCTs replacing white rice with brown rice

Risk factor	Number of studies	Mean difference (95% CI)†	I ² value for heterogeneity (%)
HDL-cholesterol (mmol/L)	11	0.06 (0.00 to 0.11)	65.28
HOMA-IR	6	-0.14 (-0.43 to 0.15)	0.00
Total cholesterol (mmol/L)	10	-0.07 (-0.23 to 0.09)	58.37
HbA1c (%)	7	-0.05 (-0.14 to 0.05)	42.66
Triglycerides (mmol/L)	11	-0.00 (-0.01 to 0.01)	0.00
LDL-cholesterol (mmol/L)	11	-0.05 (-0.25 to 0.16)	82.95
Fasting blood glucose (mmol/L)	11	-0.06 (-0.23 to 0.11)	59.56
Systolic blood pressure (mm Hg)	8	-3.73 (-7.04 to -0.41)	76.22
Diastolic blood pressure (mm Hg)	8	-2.26 (-4.54 to 0.01)	78.55
Waist circumference (cm)	8	-0.79 (-2.11 to 0.53)	76.97

Mean difference in change from baseline (95% CI) of T2D risk factors between brown rice and white rice (control) regimens from RCTs. Trials evaluated the effect of replacing white rice with brown rice. Pooled estimates from the random-effects analysis are shown and based on a maximum of 11 RCTs (n=1034). The I² values for heterogeneity are shown. Effect estimates for individual studies along with study weights and fixed-effects models are shown in online supplemental figures 8–14. Conversion of glucose in mg/dl to mmol/l by multiplying 0.0555. Conversion of triglycerides in mg/dl to mmol/l by multiplying 0.0113. Conversion of cholesterol in mg/dl to mmol/l by multiplying 0.0259. HDL, high-density lipoprotein; LDL, low-density lipoprotein; RCTs, randomised controlled trials.

non-linearity=0.13) (figure 5). Each 50g/d (cooked weight) increment in brown rice intake was associated with a 13% lower risk of T2D (RR: 0.87; 95% CI: 0.80 to 0.94, p value for linearity=0.001).

Randomised controlled trials

The between-group difference in HDL cholesterol (0.07 mmol/L; 0.00 to 0.13 mmol/L) was statistically significant in favour of the brown rice group with moderate to high heterogeneity detected (I²=69.56%) (table 3, online supplemental figure 9). Results from the fixed-effects model were similar. There was also a significant between-group difference for systolic blood pressure in favour of the brown rice group (-3.73 mm Hg; -7.04 to -0.41) with high heterogeneity (I²=76.22%), although findings from the fixed-effects model were null, likely due to larger statistical weight being given to smaller studies in the random-effects model (table 3, online supplemental figure 10). No other between-group differences were observed (table 3, online supplemental figures 11–18). However, differences in diastolic blood pressure (-2.26 mm Hg; -4.54 to 0.01; I²=78.55%), HOMA-IR (-0.14; -0.43 to 0.15; I²=0%), total cholesterol (-0.07 mmol/L; -0.23 to 0.09 mmol/L; I²=58.37%), HbA1c (-0.05%; -0.14 to 0.05%; I²=42.66%), LDL-cholesterol (-0.05 mmol/L; -0.25 to 0.16; I²=82.95%), FBG (-0.06 mmol/L; -0.23

to 0.11; I²=59.56%), and waist circumference (-0.79 cm; -2.11 to 0.53; I²=76.97%) favoured the brown rice group.

Influence analysis

The influence analysis for cohort studies of white rice intake (online supplemental figure 19) showed a reduction in magnitude of the pooled RR with the omission of the study by Villegas *et al* (1.10; 95% CI: 0.99 to 1.22) conducted in the Shanghai Women's health Study. However, results were consistent with the overall pooled RRs, suggesting a higher risk of T2D associated with white rice intake. The lack of substantial differences in the pooled RR with the removal of the individual studies suggested that no individual study had a predominant effect on the meta-analyses. Influence analysis for meta-analyses of RCTs for outcomes that were assessed in all 11 studies (FBG, HDL-cholesterol, LDL-cholesterol and triglycerides) is shown in online supplemental figures 20–23. For FBG, when the study by Bui *et al* was removed, the pooled estimate increased (online supplemental figure 20); for HDL cholesterol when the study by Mai *et al* was removed, the pooled estimate decreased (online supplemental figure 21); and for LDL cholesterol when the study by Kazemzadeh *et al* was removed, the pooled estimate decreased, and when the study by Geng *et al* was removed, the pooled estimate increased (online supplemental figure 22). However, these changes were not material as the 95% CI of the effect estimates when individual studies were left out overlapped with the overall pooled summary estimate. Influence analysis was not conducted for cohort studies of brown rice or RCTs of other outcomes due to insufficient studies.

Publication bias

The Funnel plot for the meta-analysis of cohort studies of white rice intake and risk of T2D showed an asymmetric shape, suggesting the presence of potential publication bias (online supplemental figure 24). However, according to Egger's test (p-value, 0.68), the presence of potential publication bias is unlikely. Funnel plots for meta-analyses of RCTs for outcomes that were assessed in all 11 studies (FBG, HDL-cholesterol, LDL-cholesterol and triglycerides) are shown in online supplemental figures 25–28. Based on the shape of the plots, potential publication bias may be present in meta-analyses of HDL-cholesterol and FBG with marginal p-values from Egger's test. Publication bias was not assessed for cohort studies of brown rice or for RCTs of other outcomes due to insufficient studies.

Strength of the evidence

NutriGrade scores to assess the overall strength of the meta-evidence from cohort studies of white rice and brown rice were 6.3 and 6.4 respectively, suggesting that the strength of the evidence from these meta-analyses was moderate (online supplemental table 4). Across the individual domains of NutriGrade, the following downgrades were applied: risk of bias for studies of white rice based on



mean NOS score; heterogeneity for studies of white rice based on $I^2 \geq 40\%$; publication bias for studies of brown rice since there were < 5 studies; and effect size for studies of white rice and brown rice since pooled RRs were 0.80–1.20 comparing extreme categories. NutriGrade scores for RCTs ranged from 5.9 to 6.9 for outcomes that were assessed in all 11 studies, suggesting that the strength of the evidence from these meta-analyses was considered moderate and low. Across individual domains of NutriGrade, the following downgrades were applied: risk of bias for all outcomes based on Cochrane RoB-2; precision for LDL cholesterol, TG's and FBG since 95% CI of pooled mean difference included the null value; heterogeneity for HDL and LDL cholesterol and FBG based on $I^2 \geq 40\%$; publication bias for HDL cholesterol and FBG and funding bias for all outcomes since affiliation with private institutions and foundations were noted for some studies (online supplemental table 4).

DISCUSSION

In our meta-analysis of prospective cohort studies of rice intake and risk of T2D, we found a positive association between intake of white rice and risk of T2D. Associations appeared stronger in women compared with men, and in studies conducted in South Asia compared with China and other world regions, although differences across subgroups were not statistically significant. Overall, these findings are consistent with previous meta-analyses that also reported a positive association between white rice intake and risk of T2D.^{10 11} However, in the present meta-analysis that included a number of additional studies from other countries, we observed a linear dose–response at intake levels above 300 g/day (cooked weight) (~2 servings), suggestive of a threshold. From our subgroup analysis, it appeared that this threshold may be driven by the j-shaped association observed for studies conducted in China. In contrast, a linear dose–response association was observed for studies conducted in South Asia. The reason for this difference is not clear but could relate to regional differences in the type of rice that is consumed, other foods that are consumed with rice and how rice is prepared. It is also possible that ethnic differences in the pathophysiological response to high glycaemic load (GL) diets could be implicated.³⁶ Our meta-analysis also found an inverse association between brown rice and risk of T2D. Results from the dose–response analyses were consistent with each 50 g/day (cooked weight) increment of brown rice associated with a 13% lower risk of T2D.

While the findings of our meta-analyses of cohort studies support the replacement of white rice with brown rice for T2D risk mitigation, findings from our meta-analysis of RCTs replacing white rice with brown rice on T2D risk factors were inconsistent with a significant benefit observed only for HDL-cholesterol and SBP, although findings for SBP were null in the fixed-effects model. These results are in agreement with a previous meta-analysis of RCTs of brown rice on metabolic parameters that also found

a benefit on HDL-cholesterol,¹² although another meta-analysis of RCTs found no effect of brown rice compared with white rice on HDL-cholesterol.¹³ Both of these meta-analyses, included fewer studies than ours, and combined study populations with prediabetes and T2D, which could have different effects on metabolism. However, these meta-analyses also found a benefit of brown rice compared with white rice on body weight, which was not assessed in our meta-analysis, suggesting a therapeutic role of brown rice on weight management among patients with prediabetes and T2D.¹² Reasons for the discrepant results between our meta-analyses of cohort studies and trials may be due to the low quality and methodological limitations of the included trials including small sample size, high drop-out rates and difficulty monitoring compliance. The duration of the majority of studies ranged from 4 to 16 weeks, which may have been insufficient to detect meaningful changes in clinical indices among predominately healthy populations. In addition, the RCTs included in our meta-analysis evaluated the effect of replacing white rice with brown rice under real-world settings without participant blinding and are more an assessment of intervention delivery rather than causality.

The main difference between brown rice and white rice is in the method of processing. Polishing of white rice strips the outer bran and germ layers of the grain, resulting in the loss of fibre and other nutrients present in the bran, leaving the starchy endosperm. Unlike white rice, brown rice is not milled and contains both the germ and bran. These parts of the grain contain numerous phytochemicals including polyphenols, phytosterols and lignans, as well as vitamins, minerals, essential fatty acids and dietary fibre, many of which have been linked to T2D prevention. A meta-analysis by the WHO found consistent evidence for benefits of consuming dietary fibre and whole grains on several non-communicable diseases including T2D.⁷ Recent findings from the PURE study found that a high intake of refined grains was associated with higher risk of mortality and cardiovascular disease.³⁷ Brown rice contains nearly exclusively insoluble cereal fibre, which has been consistently associated with improved insulin sensitivity and reduced risk for T2D.^{38 39} These benefits may be due in part to the production of short-chain fatty acids in the large intestine through fermentation of fibre by gut microbiota.⁴⁰ Diets high in cereal fibre have also been linked to a low GI and GL, due to slower digestion and absorption of glucose into circulation. Previous studies have shown that diets high in GI and GL can lead to an increased glycaemic response and insulin resistance⁴¹ and have been associated with higher risk of cardiometabolic diseases and death.^{42 43} The GI of brown rice is generally lower than white rice, however, values can vary depending on the milling process, strain of rice, growing conditions and method of preparation.^{6 44 45} In our meta-analysis of RCTs, six of the nine studies specified the strain of rice or processing method, which could impact the glycaemic response. For example, in the study by Malik *et al*³⁰ parboiled brown rice was used, which

undergoes a premilling process that often leads to a lower GI although differences in parboiling techniques can yield differential impacts on GI.⁴⁶ A previous feeding trial demonstrated that parboiled brown rice but not brown rice reduced postprandial blood glucose levels compared with white rice⁴⁷ and a meta-analysis of RCTs found that pregerminated brown rice has better functional effects on the lipid profile and FBG compared with brown rice.¹³ The adverse effects of high GI and GL diets tend to be more pronounced in individuals with excess adiposity, who are more likely to have insulin-resistance compared with lean individuals.⁴⁸ Since our meta-analysis was conducted among predominantly healthy populations and we were unable to stratify by weight status given the available data, we were not able to explore that relation.

Subgroup findings from our meta-analysis showed that the positive association between white rice and risk of T2D was strongest in studies conducted in South Asia compared with studies in Chinese populations or other parts of the world, although differences were not statistically significant. Of note, three of the four studies conducted among Chinese populations showed no association between white rice and risk of T2D. This could be due in part to intake of vegetables, meat and seafood with rice in mixed dishes that is typical in the Chinese diet, which can reduce dietary GL. In countries in South Asia, such as India, high intakes of white rice are consumed in the context of diets low in protein and other nutrients, which may be a key regional driver of T2D risk.¹⁷ The differential associations between white rice and T2D risk across Asian populations warrants further investigation.

This systematic review and meta-analysis on rice intake and risk of T2D is the most comprehensive synthesis of the evidence to date that includes findings from both prospective cohort studies of hard endpoints and trials of intermediate cardiometabolic risk factors. Key strengths include the large sample size and long duration of follow-up of cohort studies from different parts of the world. We also used systematic methods including risk of bias and evidence grading specific for nutrition research, conducted categorical and dose–response analyses and a number of sensitivity analyses to assess the robustness of our results.

Rice, predominantly consumed as a refined grain, is a staple food for more than 50% of the world's population.⁴⁹ Our findings have broad implications given the widespread consumption of rice particularly in LMICs where T2D and related comorbidities are rapidly rising. However, several limitations should be noted. Only three cohorts with data on brown rice consumption⁸ were included in the meta-analysis, all of which were conducted among predominantly white health professionals in the USA with fairly low intake. Although these studies were adjusted for a number of lifestyle factors, residual confounding remains a concern and generalisability of the findings to other populations is limited. We had too few studies to conduct subgroup analyses for cohort studies of brown rice and RCT outcomes. Our categorisation of

geographic regions into China, South Asia and the rest of the world may have masked the effects of cultural variation in the diet in individual countries and ethnic/racial variations in T2D risk as we were unable to extract data on ethnicity. Despite conducting several subgroup analyses, heterogeneity persisted in our meta-analysis of white rice intake in cohort studies. Although individual cohort studies adjusted for a number of confounders including diet quality, residual confounding remains a concern, particularly by socioeconomic status. However, the majority of cohort studies were considered to be of good or fair quality, while RCTs were considered to have low or some concern for risk of bias. Finally, the overall strength of the meta-evidence from cohort studies was considered moderate and moderate and low for RCTs. There are no RCTs with hard endpoints on this topic, thus the assessment of rice intake on T2D risk relies on observational studies and trials of limited quality on intermediate risk factors. As randomised trials comparing brown rice with white rice on T2D incidence as the endpoint may not be feasible, further RCTs on intermediate risk factors and cohort studies comparing white rice with brown rice and other whole grains would be useful.

In conclusion, this systematic review and meta-analyses provides additional support for a positive association between white rice intake and risk of T2D. Findings also suggest that brown rice is inversely associated with risk of T2D, although results are based on limited data. Replacing white rice with brown rice or other whole grains has the potential to be a low-cost and feasible lifestyle strategy to improve diet quality and help reduce T2D risk.

Author affiliations

¹Department of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada

²Women's College Hospital, Toronto, Ontario, Canada

³Department of Nutritional Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada

⁴Department of Food and Nutrition Research, Madras Diabetes Research Foundation, Chennai, Tamil Nadu, India

⁵School of Health and Related Research, The University of Sheffield, Sheffield, UK

⁶Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK

⁷Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA

⁸Department of Nutrition, Harvard University T H Chan School of Public Health, Boston, Massachusetts, USA

⁹Risk Factor Modification Centre, St. Michael's Hospital, Toronto, Ontario, Canada

¹⁰Department of Diabetology, Madras Diabetes Research Foundation, Chennai, Tamil Nadu, India

Contributors VSM conceived of the study. JY and VSM wrote the study protocol and designed the analysis. JY registered the protocol and conducted the literature search. JY, MT, SJ and VSM assessed the eligibility of studies for inclusion in the analysis. JY and VSM had access to, and verified, the underlying data from all original research articles. Statistical analyses and evidence grading were done by JY with guidance from TK and checked by VSM. JY and BB wrote the first draft of the manuscript. SV, VR, AP, SB, QS, WW, FBH, DJAJ and VSM interpreted the data and critically reviewed the manuscript for important intellectual content. VSM had final responsibility to submit the manuscript for publication and is the guarantor.

Funding This study received no external funding. VSM is supported by the Canada Research Chair programme. We thank authors who provided additional data for meta-analysis.

Competing interests DJAJ has received research grants from Loblaw Companies, the Almond Board of California, Soy Nutrition Institute (SNI) and the Canadian Institutes of Health Research (CIHR). He has received in-kind supplies for trials as a research support from the Almond board of California, Walnut Council of California, the Peanut Institute, Barilla, Unilever, Unico, Primo, Loblaw Companies, Quaker (Pepsico), Pristine Gourmet, Bunge Limited, Kellogg Canada, WhiteWave Foods. He has been on the speaker's panel, served on the scientific advisory board and/or received travel support and/or honoraria from Nutritional Fundamentals for Health (NFH)-Nutramedica, Saint Barnabas Medical Center, The University of Chicago, 2020 China Glycaemic Index (GI) International Conference, Atlantic Pain Conference, Academy of Life Long Learning, Loblaw Companies, Diet Quality Photo Navigation (DQPN), Better Therapeutics (FareWell), Verywell, True Health Initiative (THI), Heali AI Corp, Institute of Food Technologists (IFT), Soy Nutrition Institute (SNI), Herbalife Nutrition Institute (HNI), Herbalife International, Pacific Health Laboratories, Nutritional Fundamentals for Health (NFH), the Soy Foods Association of North America, the Nutrition Foundation of Italy (NFI), the Toronto Knowledge Translation Group (St. Michael's Hospital), the Canadian College of Naturopathic Medicine, The Hospital for Sick Children, the Canadian Nutrition Society (CNS) and the American Society of Nutrition (ASN). He is a member of the International Carbohydrate Quality Consortium (ICQC). His wife, Alexandra L Jenkins, is a director and partner of INQUIS Clinical Research for the Food Industry, his two daughters, Wendy Jenkins and Amy Jenkins, have published a vegetarian book that promotes the use of the low glycaemic index plant foods advocated here, The Portfolio Diet for Cardiovascular Risk Reduction (Academic Press/Elsevier 2020 ISBN:978-0-12-810510-8) and his sister, Caroline Brydson, received funding through a grant from the St. Michael's Hospital Foundation to develop a cookbook for one of his studies. He is also vegan. VSM and SV are involved in the production and distribution of brown rice. VSM has developed a healthier variety of white rice and is involved in studies on glycaemic index of various rice varieties. TK has received research support from the International Life Science Institute (ILSI), and the National Honey Board. VSM is a consultant for the Nutrition Guidance Expert Advisory Group for the WHO. SB is a scientific consultant for Layer IV for work that is unrelated to this manuscript. There are no other financial or personal conflicts of interest to disclose that are related to the contents of this manuscript. The funding sources had no role in study design; in the collection, analysis and interpretation of data; in the writing of the report or in the decision to submit the article for publication. The authors are not affiliated with the funding institutions.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. The study data set can be requested from VSM: vasanti.malik@utoronto.ca.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

David J A Jenkins <http://orcid.org/0000-0003-1192-9571>

Vasanti S Malik <http://orcid.org/0000-0002-9453-4796>

REFERENCES

- Saeedi P, Petersohn I, Salpea P, *et al*. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. *Diabetes Res Clin Pract* 2019;157:107843.

- Malik VS, Willett WC, Hu FB. Global obesity: trends, risk factors and policy implications. *Nat Rev Endocrinol* 2013;9:13–27.
- Mattei J, Malik V, Wedick NM, *et al*. Reducing the global burden of type 2 diabetes by improving the quality of staple foods: the global nutrition and epidemiologic transition initiative. *Global Health* 2015;11:23.
- Aune D, Keum N, Giovannucci E, *et al*. Whole grain consumption and risk of cardiovascular disease, cancer, and all cause and cause specific mortality: systematic review and dose-response meta-analysis of prospective studies. *BMJ* 2016;353:i2716.
- Atkinson FS, Foster-Powell K, Brand-Miller JC. International tables of glycemic index and glycemic load values: 2008. *Diabetes Care* 2008;31:2281–3.
- Atkinson FS, Brand-Miller JC, Foster-Powell K, *et al*. International tables of glycemic index and glycemic load values 2021: a systematic review. *Am J Clin Nutr* 2021;114:1625–32.
- Reynolds A, Mann J, Cummings J, *et al*. Carbohydrate quality and human health: a series of systematic reviews and meta-analyses. *Lancet* 2019;393:434–45.
- Sun Q, Spiegelman D, van Dam RM, *et al*. White rice, brown rice, and risk of type 2 diabetes in US men and women. *Arch Intern Med* 2010;170:961–9.
- Hu Y, Ding M, Sampson L, *et al*. Intake of whole grain foods and risk of type 2 diabetes: results from three prospective cohort studies. *BMJ* 2020;370:m2206.
- Hu EA, Pan A, Malik V, *et al*. White rice consumption and risk of type 2 diabetes: meta-analysis and systematic review. *BMJ* 2012;344:e1454.
- Ren G, Qi J, Zou Y. Association between intake of white rice and incident type 2 diabetes - An updated meta-analysis. *Diabetes Res Clin Pract* 2021;172:108651.
- Abdul Rahim AF, Norhayati MN, Zainudin AM. The effect of a brown-rice diets on glycemic control and metabolic parameters in prediabetes and type 2 diabetes mellitus: a meta-analysis of randomized controlled trials and controlled clinical trials. *PeerJ* 2021;9:e11291.
- Golzarand M, Toolabi K, Eskandari Delfan S, *et al*. The effect of brown rice compared to white rice on adiposity indices, lipid profile, and glycemic markers: a systematic review and meta-analysis of randomized controlled trials. *Crit Rev Food Sci Nutr* 2021;17:1–18.
- Higgins JPT, Thomas J, Chandler J, eds. *Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022)*, 2022. www.training.cochrane.org/handbook
- Ren C, Hong B, Zheng X, *et al*. Improvement of germinated brown rice quality with autoclaving treatment. *Food Sci Nutr* 2020;8:1709–17.
- Tufanaru C, Munn Z, Stephenson M, *et al*. Fixed or random effects meta-analysis? Common methodological issues in systematic reviews of effectiveness. *Int J Evid Based Healthc* 2015;13:196–207.
- Bhavadharini B, Mohan V, Dehghan M, *et al*. White rice intake and incident diabetes: a study of 132,373 participants in 21 countries. *Diabetes Care* 2020;43:2643–50.
- Seah JYH, Koh W-P, Yuan J-M, *et al*. Rice intake and risk of type 2 diabetes: the Singapore Chinese Health Study. *Eur J Nutr* 2019;58:3349–60.
- Hodge AM, English DR, O'Dea K, *et al*. Glycemic index and dietary fiber and the risk of type 2 diabetes. *Diabetes Care* 2004;27:2701–6.
- Bekkering GE, Harris RJ, Thomas S, *et al*. How much of the data published in observational studies of the association between diet and prostate or bladder cancer is usable for meta-analysis? *Am J Epidemiol* 2008;167:1017–26.
- Schwingshackl L, Knüppel S, Schwedhelm C, *et al*. Perspective: NutriGrade: a scoring system to assess and judge the Meta-Evidence of randomized controlled trials and cohort studies in nutrition research. *Adv Nutr* 2016;7:994–1004.
- Villegas R, Liu S, Gao Y-T, *et al*. Prospective study of dietary carbohydrates, glycemic index, glycemic load, and incidence of type 2 diabetes mellitus in middle-aged Chinese women. *Arch Intern Med* 2007;167:2310–6.
- Nanri A, Mizoue T, Noda M, *et al*. Rice intake and type 2 diabetes in Japanese men and women: the Japan public health center-Based prospective study. *Am J Clin Nutr* 2010;92:1468–77.
- Soriguer F, Colomo N, Oliveira G, *et al*. White rice consumption and risk of type 2 diabetes. *Clin Nutr* 2013;32:481–4.
- Golzar A, Khalili D, Etemadi A, *et al*. White rice intake and incidence of type-2 diabetes: analysis of two prospective cohort studies from Iran. *BMC Public Health* 2017;17:133.
- Zhang G, Pan A, Zong G, *et al*. Substituting white rice with brown rice for 16 weeks does not substantially affect metabolic risk factors in middle-aged Chinese men and women with diabetes or a high risk for diabetes. *J Nutr* 2011;141:1685–90.

- 27 Wang B, Medapalli R, Xu J, *et al.* Effects of a whole rice diet on metabolic parameters and inflammatory markers in prediabetes. *Espen J* 2013;8:e15–20.
- 28 Kazemzadeh M, Safavi SM, Nematollahi S, *et al.* Effect of brown rice consumption on inflammatory marker and cardiovascular risk factors among overweight and obese non-menopausal female adults. *Int J Prev Med* 2014;5:478–88.
- 29 Araki R, Ushio R, Fujie K, *et al.* Effect of partially-abraded brown rice consumption on body weight and the indicators of glucose and lipid metabolism in pre-diabetic adults: a randomized controlled trial. *Clin Nutr ESPEN* 2017;19:9–15.
- 30 Malik VS, Sudha V, Wedick NM, *et al.* Substituting brown rice for white rice on diabetes risk factors in India: a randomised controlled trial. *Br J Nutr* 2019;121:1389–97.
- 31 Mai TT, Trang TT, Hai TT. Effectiveness of germinated brown rice on metabolic syndrome: a randomized control trial in Vietnam. *AIMS Public Health* 2020;7:33–43.
- 32 Geng S, Zhu Y, Zhang J. Lowering effect of pre-germinated brown rice on dyslipidemia in Chinese patients. *Int J Clin Exp Med* 2016;9:22317–23.
- 33 Kuroda Y, Matsuzaki K, Wakatsuki H, *et al.* Influence of ultra-high hydrostatic pressurizing brown rice on cognitive functions and mental health of elderly Japanese individuals: a 2-year randomized and controlled trial. *J Nutr Sci Vitaminol* 2019;65:S80–7.
- 34 Shimabukuro M, Higa M, Kinjo R, *et al.* Effects of the brown rice diet on visceral obesity and endothelial function: the BRAVO study. *Br J Nutr* 2014;111:310–20.
- 35 Bui TN, Le TH, Nguyen DH, *et al.* Pre-germinated brown rice reduced both blood glucose concentration and body weight in Vietnamese women with impaired glucose tolerance. *J Nutr Sci Vitaminol* 2014;60:183–7.
- 36 Narayan KMV, Kanaya AM. Why are South Asians prone to type 2 diabetes? A hypothesis based on underexplored pathways. *Diabetologia* 2020;63:1103–9.
- 37 Swaminathan S, Dehghan M, Raj JM, *et al.* Associations of cereal grains intake with cardiovascular disease and mortality across 21 countries in prospective urban and rural epidemiology study: prospective cohort study. *BMJ* 2021;372:m4948.
- 38 InterAct Consortium. Dietary fibre and incidence of type 2 diabetes in eight European countries: the EPIC-InterAct study and a meta-analysis of prospective studies. *Diabetologia* 2015;58:1394–408.
- 39 Weickert MO, Pfeiffer AFH. Metabolic effects of dietary fiber consumption and prevention of diabetes. *J Nutr* 2008;138:439–42.
- 40 Nogal A, Valdes AM, Menni C. The role of short-chain fatty acids in the interplay between gut microbiota and diet in cardio-metabolic health. *Gut Microbes* 2021;13:1–24.
- 41 Ludwig DS. The glycemic index: physiological mechanisms relating to obesity, diabetes, and cardiovascular disease. *JAMA : the journal of the American Medical Association* 2002;287:2414–23.
- 42 Bhupathiraju SN, Tobias DK, Malik VS, *et al.* Glycemic index, glycemic load, and risk of type 2 diabetes: results from 3 large US cohorts and an updated meta-analysis. *Am J Clin Nutr* 2014;100:218–32.
- 43 Jenkins DJA, Dehghan M, Mente A, *et al.* Glycemic index, glycemic load, and cardiovascular disease and mortality. *N Engl J Med* 2021;384:1312–22.
- 44 RamyaBai M, Wedick NM, Shanmugam S, *et al.* Glycemic index and microstructure evaluation of four cereal grain foods. *J Food Sci* 2019;84:3373–82.
- 45 Shobana S, Lakshmi Priya N, Bai MR, *et al.* Even minimal polishing of an Indian parboiled brown rice variety leads to increased glycemic responses. *Asia Pac J Clin Nutr* 2017;26:829–36.
- 46 Boers HM, Seijen Ten Hoorn J, Mela DJ. A systematic review of the influence of rice characteristics and processing methods on postprandial glycaemic and insulinaemic responses. *Br J Nutr* 2015;114:1035–45.
- 47 Hamad S, Zafar TA, Sidhu J. Parboiled rice metabolism differs in healthy and diabetic individuals with similar improvement in glycemic response. *Nutrition* 2018;47:43–9.
- 48 Ding EL, Malik VS. Convergence of obesity and high glycemic diet on compounding diabetes and cardiovascular risks in modernizing China: an emerging public health dilemma. *Global Health* 2008;4:4.
- 49 Fukagawa NK, Ziska LH. Rice: importance for global nutrition. *J Nutr Sci Vitaminol* 2019;65:S2–3.

Supplementary material for: White Rice, Brown Rice and the Risk of Type 2 Diabetes: A Systematic Review and Meta-Analysis.

Table of contents:

Supplemental Table 1: Search terms used in literature search of databases. **Page 4.**

Supplemental Table 2: Relative risk estimates and covariate adjustment of included cohort studies of white rice and brown rice and risk of type 2 diabetes. **Page 5**

Supplemental Table 3: Mean difference and standard error (SE) in T2D risk factors between brown rice and white rice groups from RCTs. **Page 8**

Supplemental Table 4: Overall meta-evidence quality assessment using NutriGrade. **Page 10**

Supplemental figure 1: Forest-plot of white rice intake and risk of T2D stratified by sex. **Page 11**

Supplemental figure 2: Forest-plot of white rice intake and risk of T2D stratified by age. **Page 13**

Supplemental figure 3: Forest-plot of white rice intake and risk of T2D stratified by duration of follow-up. **Page 15**

Supplemental figure 4: Forest-plot of white rice intake and risk of T2D stratified by adjustment for diet quality. **Page 17**

Supplemental figure 5: Forest-plot of white rice intake and risk of T2D stratified by geographic region. **Page 19**

Supplemental figure 6: Forest-plot of white rice intake and risk of T2D stratified by typical rice consuming habits. **Page 21**

Supplemental Figure 7: Fixed-effects cubic spline for intake of white rice in relation to risk of T2D stratified by geographical region. **Page 23**

Supplemental Figure 8: Fixed-effects cubic spline for intake of white rice in relation to risk of T2D stratified by rice consumption habits of region. **Page 24**

Supplemental figure 9: Forest plot of mean difference in HDL cholesterol level between white rice and brown rice groups in RCTs. **Page 25**

Supplemental figure 10: Forest plot of mean difference in systolic blood pressure between white rice and brown rice groups in RCTs. **Page 26**

Supplemental figure 11: Forest plot of mean difference in diastolic blood pressure between white rice and brown rice groups in RCTs. **Page 27**

Supplemental figure 12: Forest plot of mean difference in insulin resistance, HOMA-IR between white rice and brown rice groups in RCTs. **Page 28**

Supplemental figure 13: Forest plot of mean difference in total cholesterol between white rice and brown rice groups in RCTs. **Page 29**

Supplemental figure 14: Forest plot of mean difference in HbA1c between white rice and brown rice groups in RCTs. **Page 30**

Supplemental figure 15: Forest plot of mean difference in triglycerides between white rice and brown rice groups in RCTs. **Page 31**

Supplemental figure 16: Forest plot of mean difference in LDL cholesterol between white rice and brown rice groups in RCTs. **Page 32**

Supplemental figure 17: Forest plot of mean difference in fasting blood glucose (FBG) between white rice and brown rice groups in RCTs. **Page 33**

Supplemental figure 18: Forest plot of mean difference in waist circumference between white rice and brown rice groups in RCTs. **Page 34**

Supplemental figure 19: Influence analysis of individual prospective cohort studies in the meta-analysis of white rice intake and risk of T2D. **Page 35**

Supplemental figure 20: Influence analysis of individual RCTs replacing white rice with brown rice in the meta-analysis of fasting blood glucose. **Page 36**

Supplemental figure 21: Influence analysis of individual RCTs replacing white rice with brown rice in the meta-analysis of HDL cholesterol. **Page 37**

Supplemental figure 22: Influence analysis of individual RCTs replacing white rice with brown rice in the meta-analysis of LDL cholesterol. **Page 38**

Supplemental figure 23: Influence analysis of individual RCTs replacing white rice with brown rice in the meta-analysis of triglycerides. **Page 39**

Supplemental figure 24: Funnel plot for meta-analysis of prospective cohort studies of white rice (WR) intake and risk of T2D. **Page 40**

Supplemental figure 25: Funnel plot for meta-analysis of RCTs replacing white rice with brown rice for fasting blood glucose. **Page 41**

Supplemental figure 26: Funnel plot for meta-analysis of RCTs replacing white rice with brown rice for HDL cholesterol. **Page 42**

Supplemental figure 27: Funnel plot for meta-analysis of RCTs replacing white rice with brown rice for LDL cholesterol. **Page 43**

Supplemental figure 28: Funnel plot for meta-analysis of RCTs replacing white rice with brown rice for triglycerides. **Page 44.**

Supplemental Table 1: Search terms used in literature search of databases

Steps	Search terms
1	'Oryza sativa'[MeSH] OR 'oryza sativa'[tiab] OR 'rice'[tiab] OR 'grain'[tiab] OR 'grains'[tiab] OR 'brown rice'[tiab] OR 'white rice'[tiab]
2	'Diabetes Mellitus'[MeSH] OR 'diabetes'[tiab] OR 'diabetes mellitus'[tiab]
3	'insulin'[tiab] OR 'glucose'[tiab] OR 'HDL'[tiab] OR 'high-density lipoprotein'[tiab] OR 'LDL'[tiab] OR 'low-density lipoprotein'[tiab] OR 'cholesterol'[tiab] OR 'triglyceride'[tiab] OR 'triglycerides'[tiab] OR 'glycosylated hemoglobin'[tiab]
4	#2 OR #3
5	#1 AND #4
6	Result (Limit to #5 to Human Studies)

Supplemental Table 2: Relative risk estimates and covariate adjustment of included cohort studies of white rice and brown rice and risk of type 2 diabetes

Author	Location and study population	Relative Risk (95% CI) [intake level] [†]	Adjustments
White rice			
Hodge, 2004	Australia. Melbourne Collaborative Cohort Study (MCCS)	1.0 (ref.) [$<23\text{g/d}$]; 0.77 (0.56 to 1.07) [$23\text{-}22\text{g/d}$]; 0.91 (0.67 to 1.22) [$33\text{-}55\text{g/d}$]; 0.93 (0.68 to 1.27) [$\geq 56\text{g/d}$]	Age, sex, country of birth, physical activity, family history of diabetes, alcohol, total energy intake, education, 5-year weight change, body mass index (BMI), and waist-hip ratio (WHR)
Villegas, 2007	China. Shanghai Women's Health Study (SWHS)	1 (ref.) [$<500\text{g/d}$]; 1.04 (0.86, 1.25) [$500\text{-}622.5\text{g/d}$]; 1.29 (1.08, 1.54) [$625\text{-}747.5\text{g/d}$]; 1.78 (1.48, 2.15) [$\geq 750\text{g/d}$]	Age, daily kilocalories consumption, BMI, WHR, smoking status, alcohol consumption, physical activity, income level, education level, occupation, diagnosis of hypertension
Nanri, 2010	Japan. Japan Public Health Center-based Prospective Study (JPHC)	1 (ref.) [$<315\text{g/d}$]; 1.24 (1.00, 1.55) [$315\text{-}420\text{g/d}$]; 1.25 (0.93, 1.67) [$420\text{-}560\text{g/d}$]; 1.19 (0.85, 1.68) [$>560\text{g/d}$]	Age, study area, smoking status, alcohol consumption, family history of diabetes, total physical activity, history of hypertension, occupation, total energy intake, coffee consumption, dietary intakes (calcium, magnesium, fiber, fruit, vegetables, fish, rice, bread, and noodles), BMI
Nanri, 2010	Japan. Japan Public Health Center-based Prospective Study (JPHC)	1 (ref.) [$<278\text{g/d}$]; 1.15 (0.85, 1.55) [$280\text{-}417\text{g/d}$]; 1.48 (1.08, 2.02) [$420\text{-}420\text{g/d}$]; 1.65 (1.06, 2.57) [$\geq 437\text{g/d}$]	Same as above
Sun, 2010	United States. Health Professionals Follow-up Study (HPFS)	1 (ref.) [$<5.3\text{g/d}$]; 1.09 (0.96, 1.24) [$5.3\text{-}15.8\text{g/d}$]; 1.07 (0.93, 1.23) [$15.9\text{-}45\text{g/d}$]; 1.30 (1.12, 1.50) [$45.1\text{-}112.9\text{g/d}$]; 1.02 (0.77, 1.34) [$\geq 112.9\text{g/d}$]	Age, ethnicity, BMI, smoking status, alcohol intake, multivitamin use, physical activity, family history of diabetes, total energy and intake of red meat, fruits and vegetables, whole grains, and coffee
Sun, 2010	United States. Nurses' Health Study (NHS)	1 (ref.) [$<5.3\text{g/d}$]; 1.00 (0.90, 1.11) [$5.3\text{-}15.8\text{g/d}$]; 1.07 (0.96, 1.20) [$15.9\text{-}45\text{g/d}$]; 1.09 (0.97, 1.23) [$45.1\text{-}112.9$]; 1.11 (0.87, 1.43) [$\geq 112.9\text{g/d}$]	Same as above, with the further adjustments of postmenopausal status, hormone use, and oral contraceptive use
Sun, 2010	United States. Nurses' Health Study II (NHS II)	1 (ref.) [$<5.3\text{g/d}$]; 0.93 (0.81, 1.07) [$5.3\text{-}15.8\text{g/d}$]; 0.94 (0.81, 1.10) [$15.9\text{-}45\text{g/d}$]; 0.95 (0.81, 1.11) [$45.1\text{-}112.9\text{g/d}$];	Same as above

		1.40 (1.09, 1.80) [$\geq 112.9\text{g/d}$]	
Soriguer, 2013	Spain. Pizarra study (PS)	1 (ref.) [$\leq 22.57\text{g/d}$]; 0.41 (0.17, 0.98) [45.1-67.7g/d]	Age, sex, obesity and abnormal glucose regulation at baseline, carbohydrate consumption
Golozar, 2017	Iran. Golestan Cohort Study (GCS)	1 (ref.) [$\leq 71.1\text{g/d}$]; 1.00 (0.78, 1.29) [71.2-120g/d]; 1.03 (0.77, 1.38) [120.1-210g/d]; 1.11 (0.83, 1.49) [$> 210\text{g/d}$]	Age, sex, ethnicity, wealth score, education, marital status, employment status, opium, alcohol, occupational physical activity, smoking, quartiles of daily meat intake, quartiles of daily calorie intake, BMI
Golozar, 2017	Iran. Golestan Cohort Study (GCS)	1 (ref.) [$\leq 71.1\text{g/d}$]; 0.70 (0.50, 0.98) [71.2-120g/d]; 0.85 (0.61, 1.18) [120.1-210g/d]; 0.95 (0.69, 1.30) [$> 210\text{g/d}$]	Same as above
Golozar, 2017	Iran. Tehran Lipid and Glucose Study (TLGS)	1 (ref.) [$< 250\text{g/d}$]; 0.88 (0.42, 1.83) [250g/d]; 1.52 (0.57, 4.07) [$> 250\text{g/d}$]	Age, sex, family history of T2D, education, marital status, employment status, total physical activity, smoking, quartiles of daily meat intake, quartiles of daily calorie intake, BMI
Golozar, 2017	Iran. Tehran Lipid and Glucose Study (TLGS)	1 (ref.) [$< 250\text{g/d}$]; 0.88 (0.42, 1.83) [250g/d]; 1.52 (0.57, 4.07) [$> 250\text{g/d}$]	Same as above
Seah, 2018	Chinese living in Singapore. Singapore Chinese Health Study (SCHS)	1 (ref.) [238.1g/d]; 1.05 (0.94, 1.18) [333.7g/d]; 1.02 (0.91, 1.14) [402.7g/d]; 0.97 (0.86, 1.09) [474.4g/d]; 1.03 (0.90, 1.17) [570.2g/d]	Sex, father's dialect, year of interview, cigarette smoking, education level, physical activity, BMI, history of hypertension, Alternative Healthy Eating Index -- 2010
Seah, 2018	Chinese living in Singapore. Singapore Chinese Health Study (SCHS)	1 (ref.) [234.0g/d]; 0.92 (0.79, 1.06) [334.1g/d]; 0.96 (0.83, 1.11) [404.0g/d]; 0.99 (0.86, 1.15) [473.8g/d]; 0.94 (0.83, 1.07) [683.2g/d]	Same as above
Bhavadharini, 2020	21 countries. Prospective Urban Rural Epidemiology Study (PURE)	1 (ref.) [$< 150\text{g/d}$]; 1.12 (1.01-1.24) [150-300g/d]; 1.25 (1.10-1.43) [300-450g/d]; 1.20 (1.02-1.40) [$> 450\text{g/d}$]	Age, sex, BMI, WHR, family history of diabetes, smoking, location, education, wealth index, physical activity, energy intake, whole grains, refined grains, fruit and vegetables
Brown rice			
Sun, 2010	United States. Health Professionals Follow-up Study (HPFS)	1 (ref.) [$< 6.5\text{g/d}$]; 0.96 (0.89, 1.04) [6.5-27.86g/d]; 0.96 (0.82, 1.12) [$\geq 55.7\text{g/d}$]	Age, ethnicity, body mass index, smoking status, alcohol intake, multivitamin use, physical activity, family history of diabetes, total energy and intake of red meat, fruits and vegetables, whole grains, and coffee

Sun, 2010	Nurses' Health Study (NHS)	1 (ref.) [$<6.5\text{g/d}$]; 0.92 (0.87, 0.98) [$6.5\text{-}27.86\text{g/d}$]; 0.83 (0.72, 0.96) [$\geq 55.7\text{g/d}$]	Same as above, with the further adjustments of postmenopausal status, hormone use, and oral contraceptive use
Sun, 2010	Nurses' Health Study II (NHS II)	1 (ref.) [$<6.5\text{g/d}$]; 0.95 (0.87, 1.04) [$6.5\text{-}27.86\text{g/d}$]; 0.89 (0.75, 1.07) [$\geq 55.7\text{g/d}$]	Same as above

‡ Serving size assumption of cooked rice is 158 g; conversion of raw rice to cooked rice by multiplying 2.5

Supplemental Table 3: Mean difference and standard error (SE) in T2D risk factors between brown rice and white rice groups from included RCTs

Author	HbA1c ± SE (%)	TC ± SE (mmol/L)	LDL ± SE (mmol/L)	HDL ± SE (mmol/L)	TG ± SE (mmol/L)	FBG ± SE (mmol/L)	HOMA-IR	SBP ± SE (mmHg)	DBP ± SE (mmHg)	WC ± SE (cm)
Zhang, 2011	-0.07 ± 0.09	0.29 ± 0.15	0.3 ± 0.13	0.07 ± 0.04	-0.05 ± 0.1	0.13 ± 0.18	0.04 ± 0.22	-0.21 ± 1.35	0.42 ± 0.86	0.27 ± 0.35
Wang, 2013	0 ± 0.08	NA*	-0.181 ± 0.25	0.052 ± 0.13	-0.26 ± 0.45	0.222 ± 0.17	-0.2 ± 0.40	-9 ± 5.07	-4 ± 2.64	-5 ± 2.64
Kazemzadeh, 2014	-0.04 ± 0.05	0.09 ± 0.1	0.49 ± 0.1	0.08 ± 0.06	0.15 ± 0.1	0.09 ± 0.08	NA*	0.14 ± 0.26	0.8 ± 0.35	2.38 ± 0.92
Bui et al 2014	-0.88 ± 0.28	-0.88 ± 0.37	-0.47 ± 0.25	0.13 ± 0.11	-0.67 ± 0.71	-0.9 ± 0.309	NA*	-3.7 ± 7.36	-4.5 ± 3.72	-5.5 ± 2.89
Shimabukuro et al 2014	-0.07 ± 0.2	-0.14 ± 0.08	-0.1 ± 0.06	-0.02 ± 0.04	-0.06 ± 0.17	-0.9 ± 0.45	-1.7 ± 1.93	-7 ± 2.01	-2 ± 1.27	-1.7 ± 1.26
Geng, 2016	NA*	-0.52 ± 0.19	-0.76 ± 0.17	0.16 ± 0.06	-0.26 ± 0.17	-0.17 ± 0.15	NA*	-11.4 ± 3.12	-8.8 ± 1.93	-0.6 ± 1.67
Araki, 2017	0 ± 0.06	0.166 ± 0.17	0.158 ± 0.14	0.08 ± 0.05	-0.001 ± 0.01	0.194 ± 0.13	0.1 ± 0.47	NA*	NA*	-2.7 ± 0.71
Malik, 2019	-0.04 ± 0.05	-0.069 ± 0.1	-0.061 ± 0.10	-0.002 ± 0.02	-0.024 ± 0.10	-0.006 ± 0.10	-0.2 ± 0.33	NA*	NA*	-0.01 ± 0.55
Kuroda, 2019	0.1 ± 0.2	-0.233 ± 0.37	-0.161 ± 0.34	0.08 ± 0.17	-0.33 ± 0.43	0.733 ± 0.82	NA*	4 ± 9.85	-1 ± 5.49	NA*
Mai, 2020	NA*	-0.2 ± 0.29	0.1 ± 0.29	0.34 ± 0.10	-0.3 ± 0.42	-0.6 ± 0.29	-1 ± 0.498	-2.1 ± 4.90	-3.4 ± 4.16	NA*
Ren, 2020	NA*	0.1 ± 0.47	-0.11 ± 0.33	-0.08 ± 0.05	0.36 ± 0.27	-0.28 ± 0.51	NA*	NA*	NA*	NA*

* NA not available

T2D = Type 2 diabetes; HbA1c = Hemoglobin A1C; TC = Total cholesterol; LDL = low-density lipoprotein cholesterol; HDL = high-density lipoprotein cholesterol; TG = Triglycerides; FBG = Fasting blood glucose; HOMA-IR = Assessment of insulin resistance; SBP = Systolic blood pressure; DBP = Diastolic blood pressure; WC = Waist circumference.


Conversion of glucose in mg/dl to mmol/l by multiplying 0.0555. Conversion of TAG in mg/dl to mmol/l by multiplying 0.0113. Conversion of cholesterol in mg/dl to mmol/l by multiplying 0.0259.

Supplemental Table 4: Overall meta-evidence quality assessment using NutriGrade

<i>Study</i>	<i>Risk of bias</i>	<i>Precision</i>	<i>Heterogeneity</i>	<i>Directness</i>	<i>Publication bias</i>	<i>Funding bias</i>	<i>Effect size</i>	<i>Dose-response</i>	<i>Overall</i>	<i>Assessment</i>
<i>Cohort - BR</i>	2	1	0.4	1	0	1	0	1	6.4	Moderate meta-evidence
<i>Cohort - WR</i>	1	1	0.3	1	1	1	0	1	6.3	Moderate meta-evidence
<i>Study</i>	<i>Risk of bias</i>	<i>Precision</i>	<i>Heterogeneity</i>	<i>Directness</i>	<i>Publication bias</i>	<i>Funding bias</i>	<i>Study design*</i>	<i>Overall</i>	<i>Assessment</i>	
<i>RCTs - LDL cholesterol</i>	1.5	0	0.4	1	1	0.5	2	6.4	Moderate meta-evidence	
<i>RCTs - HDL cholesterol</i>	1.5	1	0.4	1	0.5	0.5	2	6.9	High meta-evidence	
<i>RCTs - TGs</i>	1.5	0	0.8	1	1	0.5	2	6.8	Moderate meta-evidence	
<i>RCTs - FBG</i>	1.5	0	0.4	1	0.5	0.5	2	5.9	Moderate meta-evidence	

The assessment is based on the overall score: 0-3.99 = very low meta-evidence; 4-5.99 = low meta-evidence; 6-7.99 = moderate meta-evidence; ≥ 8 = high meta-evidence. BR, brown rice; WR, white rice; TGs, triglycerides, FBG, fasting blood glucose.


* For the randomized control trials, 2 points are automatically gained for the study design

Supplemental figure 1: Forest-plot of white rice intake and risk of T2D stratified by sex

Random-effects DerSimonian-Laird model

Risk of type 2 diabetes (T2D) (RR and 95% CI) comparing extreme categories of white rice intake from prospective cohort studies stratified by sex and overall. Horizontal lines denote 95% CIs; solid squares represent the point estimate of each study with the size proportional to study

weight. Open diamonds represent pooled estimates from the random-effects model (DerSimonian-Laird). Study weights are from the random-effects analysis. The I^2 and P values for heterogeneity are shown. The red line represents unity. M, male; F, female; MCC, Melbourne Collaborative Cohort Study; SWHS, Shanghai Women's Health Study; JPHC, Japan Public Health Center-based Prospective Study; HPFS, Health Professionals Follow-up Study; NHS, Nurses' Health Study; PS, Pizarra study; GCS, Golestan Cohort Study; TLGS, Tehran Lipid and Glucose Study; SCHS, Singapore Chinese Health Study; PURE, Prospective Urban Rural Epidemiology Study. No significant differences between groups (p-value, 0.12).


Supplemental figure 2: Forest-plot of white rice intake and risk of T2D stratified by age

Random-effects DerSimonian-Laird model

Risk of type 2 diabetes (T2D) (RR and 95% CI) comparing extreme categories of white rice intake from prospective cohort studies stratified by age and overall. Horizontal lines denote 95% CIs; solid squares represent the point estimate of each study with the size proportional to study weight. Open diamonds represent pooled estimates from the random-effects model (DerSimonian-Laird). Study weights are from the random-effects analysis. The I^2 and P values for heterogeneity are shown. The red line represents unity. M, male; F, female; MCC, Melbourne Collaborative Cohort Study; SWHS, Shanghai Women's Health Study; JPHC, Japan Public Health Center-based Prospective Study; HPFS, Health Professionals Follow-up Study; NHS,

Nurses' Health Study; PS, Pizarra study; GCS, Golestan Cohort Study; TLGS, Tehran Lipid and Glucose Study; SCHS, Singapore Chinese Health Study; PURE, Prospective Urban Rural Epidemiology Study. No significant differences between groups (p-value, 0.52).

Supplemental figure 3: Forest-plot of white rice intake and risk of T2D stratified by duration of follow-up




Random-effects DerSimonian-Laird model

Risk of type 2 diabetes (RR and 95% CI) comparing extreme categories of white rice intake from prospective cohort studies stratified by duration and overall. Horizontal lines denote 95% CIs; solid squares represent the point estimate of each study with the size proportional to study weight. Open diamonds represent pooled estimates, from the random-effects model (DerSimonian-Laird). Study weights are from the random-effects analysis. The I^2 and P values for heterogeneity are shown. The red line represents unity. M, male; F, female; MCC, Melbourne Collaborative Cohort Study; SWHS, Shanghai Women's Health Study; JPHC, Japan Public

Health Center-based Prospective Study; HPFS, Health Professionals Follow-up Study; NHS, Nurses' Health Study; PS, Pizarra study; GCS, Golestan Cohort Study; TLGS, Tehran Lipid and Glucose Study; SCHS, Singapore Chinese Health Study; PURE, Prospective Urban Rural Epidemiology Study. No significant differences between groups (p-value, 0.40).

Supplemental figure 4: Forest-plot of white rice intake and risk of T2D stratified by adjustment for diet quality




Random-effects DerSimonian-Laird model

Risk of type 2 diabetes (T2D) (RR and 95% CI) comparing extreme categories of white rice intake from prospective cohort studies stratified by adjustment for diet quality and overall. Horizontal lines denote 95% CIs; solid squares represent the point estimate of each study with the size proportional to study weight. Open diamonds represent pooled estimates from the random-effects model (DerSimonian-Laird). Study weights are from the random-effects analysis. The I^2 and P values for heterogeneity are shown. The red line represents unity. M, male; F, female; MCC, Melbourne Collaborative Cohort Study; SWHS, Shanghai Women's Health Study;


JPHC, Japan Public Health Center-based Prospective Study; HPFS, Health Professionals Follow-up Study; NHS, Nurses' Health Study; PS, Pizarra study; GCS, Golestan Cohort Study; TLGS, Tehran Lipid and Glucose Study; SCHS, Singapore Chinese Health Study; PURE, Prospective Urban Rural Epidemiology Study. No significant differences between groups (p-value, 0.81).

Supplemental figure 5: Forest-plot of white rice intake and risk of T2D stratified by geographic region



Risk of type 2 diabetes (T2D) (RR and 95% CI) comparing extreme categories of white rice intake from prospective cohort studies stratified by geographic region based on the categorization in Bhavadharini et al 2020¹³. Horizontal lines denote 95% CIs; solid squares represent the point estimate of each study with the size proportional to study weight. Open diamonds represent pooled estimates from the random-effects model (DerSimonian-Laird). Study weights are from the random-effects analysis. The I^2 and P values for heterogeneity are shown. The red line represents unity. M, male; F, female; MCC, Melbourne Collaborative Cohort Study; SWHS, Shanghai Women's Health Study; JPHC, Japan Public Health Center-based Prospective Study; HPFS, Health Professionals Follow-up Study; NHS, Nurses' Health Study; PS, Pizarra study; GCS, Golestan Cohort Study; TLGS, Tehran Lipid and Glucose Study; SCHS, Singapore Chinese Health Study; PURE, Prospective Urban Rural Epidemiology Study. No significant differences between groups (p-value, 0.99).


Supplemental figure 6: Forest-plot of white rice intake and risk of T2D stratified by typical rice consuming habits



Risk of type 2 diabetes (T2D) (RR and 95% CI) comparing extreme categories of white rice intake from prospective cohort studies stratified by typical rice consumption habits. Horizontal lines denote 95% CIs; solid squares represent the point estimate of each study with the size proportional to study weight. Open diamonds represent pooled estimates from the random-effects model (DerSimonian-Laird). Study weights are from the random-effects analysis. The I^2 and P values for heterogeneity are shown. The red line represents unity. M, male; F, female; MCC, Melbourne Collaborative Cohort Study; SWHS, Shanghai Women's Health Study; JPHC, Japan Public Health Center-based Prospective Study; HPFS, Health Professionals Follow-up Study; NHS, Nurses' Health Study; PS, Pizarra study; GCS, Golestan Cohort Study; TLGS, Tehran Lipid and Glucose Study; SCHS, Singapore Chinese Health Study; PURE, Prospective Urban Rural Epidemiology Study. No significant differences between groups (p-value, 0.23).


Supplemental Figure 7: Fixed-effects cubic spline for intake of white rice in relation to risk of T2D stratified by geographical region.

Dose-response plot of White Rice Consumption by Geographic Region




Fixed-effects cubic spline for intake of white rice in relation to risk of T2D stratified by geographic region. One-stage fixed-effects dose-response model using restricted cubic splines was applied for the analysis of studies conducted in China and the rest of the world. One-stage fixed-effects dose-response model assuming a linear trend was fitted for the analysis of studies conducted in South Asia due to the limited number of observations. Black solid line represents the point estimates and the black dashed lines represent the corresponding 95% CI's. The red solid line indicates the exact linear relationship and red dashed line represents unity. Four cohorts were from China: SWHS (Villegas 2007), SCHS (Seah 2018, for both male and female), PURE (Bhavadarini 2020, China subgroup). One cohort, PURE (Bhavadarini 2020, South Asia subgroup) was from South Asia. Thirteen cohorts were included in the rest of the world: MCCS (Hodge 2004), JPHC (Nanri 2010, for both male and female), HPFS (Sun 2010), NHS (Sun 2010), NHS II (Sun 2010), PS (Soriquer 2013), GCS (Golozar 2017, for both male and female), TLGS (Golozar 2017, for both male and female), PURE (Bhavadarini 2020, The rest of the world subgroup).

Supplemental Figure 8: Fixed-effects cubic spline for intake of white rice in relation to risk of T2D stratified by rice consumption habits of region



Fixed-effects cubic spline for intake of white rice in relation to risk of T2D stratified by rice consumption habits of region. One-stage fixed-effects dose-response model using restricted cubic splines was applied for the analyses in rice-consuming countries and non-rice-consuming countries. One-stage fixed-effects dose-response model assuming a linear trend was fitted for the analysis in the rest of the world due to the limited number of observations. Black solid line represents the point estimates and the black dashed lines represent the corresponding 95% CI's. The red solid line indicates the exact linear relationship and red dashed line represents unity. Eleven cohorts were from rice-consuming countries: SWHS (Villegas 2007), JPHC (Nanri 2010, for both male and female), GCS (Golozar 2017, for both male and female), TLGS (Golozar 2017, for both male and female), SCHS (Seah 2018, for both male and female), PURE (Bhavadarini 2020, subgroups of China and South Asia). Five cohorts were from non-rice-consuming countries: MCCS (Hodge 2004), HPFS (Sun 2010), NHS (Sun 2010), NHS II (Sun 2010), PS (Soriquer 2013). One cohort was from the rest of world: PURE (Bhavadarini 2020, The rest of the world subgroup).


Supplemental figure 9: Forest plot of mean difference in high-density lipoprotein cholesterol level between white rice and brown rice groups in RCTs.



Random-effects DerSimonian-Laird model

Mean difference in change from baseline (95% CI) of HDL-cholesterol (mmol/L) between brown rice and white rice (control) regimens from RCTs. Trials evaluated the effect of replacing white rice with brown rice. Horizontal lines denote 95% CIs; solid squares represent the point estimate of each study with the size proportional to study weight. Open diamonds represent pooled estimates from the random-effects model (DerSimonian-Laird) and fixed-effects model. Study weights are from the random-effects analysis. The I^2 and P values for heterogeneity are shown.


Supplemental figure 10: Forest plot of mean difference in systolic blood pressure between white rice and brown rice groups in RCTs



Random-effects DerSimonian-Laird model

Mean difference in change from baseline (95% CI) of systolic blood pressure (mmHg) between brown rice and white rice (control) regimens from RCTs. Trials evaluated the effect of replacing white rice with brown rice. Horizontal lines denote 95% CIs; solid squares represent the point estimate of each study with the size proportional to study weight. Open diamonds represent pooled estimates from the random-effects model (DerSimonian-Laird) and fixed-effects model. Study weights are from the random-effects analysis. The I^2 and P values for heterogeneity are shown.


Supplemental figure 11: Forest plot of mean difference in diastolic blood pressure between white rice and brown rice groups in RCTs



Random-effects DerSimonian-Laird model


Mean difference in change from baseline (95% CI) of diastolic blood pressure (mmHg) between brown rice and white rice (control) regimens from RCTs. Trials evaluated the effect of replacing white rice with brown rice. Horizontal lines denote 95% CIs; solid squares represent the point estimate of each study with the size proportional to study weight. Open diamonds represent pooled estimates from the random-effects model (DerSimonian-Laird) and fixed-effects model. Study weights are from the random-effects analysis. The I^2 and P values for heterogeneity are shown.

Supplemental figure 12: Forest plot of mean difference in insulin resistance, HOMA-IR between white rice and brown rice groups in RCTs.




Mean difference in change from baseline (95% CI) of insulin resistance, HOMA-IR between brown rice and white rice (control) regimens from RCTs. Trials evaluated the effect of replacing white rice with brown rice. Horizontal lines denote 95% CIs; solid squares represent the point estimate of each study with the size proportional to study weight. Open diamonds represent pooled estimates from the random-effects model (DerSimonian-Laird) and fixed-effects model. Study weights are from the random-effects analysis. The I^2 and P values for heterogeneity are shown.

Supplemental figure 13: Forest plot of mean difference in total cholesterol between white rice and brown rice groups in RCTs.



Mean difference in change from baseline (95% CI) of total cholesterol (mmol/L) between brown rice and white rice (control) regimens from RCTs. Trials evaluated the effect of replacing white rice with brown rice. Horizontal lines denote 95% CIs; solid squares represent the point estimate of each study with the size proportional to study weight. Open diamonds represent pooled estimates from the random-effects model (DerSimonian-Laird) and fixed-effects model. Study weights are from the random-effects analysis. The I^2 and P values for heterogeneity are shown.


Supplemental figure 14: Forest plot of mean difference in HbA1c between white rice and brown rice groups in RCTs



Random-effects DerSimonian-Laird model


Mean difference in change from baseline (95% CI) of HbA1c (%) between brown rice and white rice (control) regimens from RCTs. Trials evaluated the effect of replacing white rice with brown rice. Horizontal lines denote 95% CIs; solid squares represent the point estimate of each study with the size proportional to study weight. Open diamonds represent pooled estimates from the random-effects model (DerSimonian-Laird) and fixed-effects model. Study weights are from the random-effects analysis. The I^2 and P values for heterogeneity are shown.

Supplemental figure 15: Forest plot of mean difference in triglycerides between white rice and brown rice groups in RCTs



Mean difference in change from baseline (95% CI) of triglycerides (mmol/L) between brown rice and white rice (control) regimens from RCTs. Trials evaluated the effect of replacing white rice with brown rice. Horizontal lines denote 95% CIs; solid squares represent the point estimate of each study with the size proportional to study weight. Open diamonds represent pooled estimates from the random-effects model (DerSimonian-Laird) and fixed-effects model. Study weights are from the random-effects analysis. The I^2 and P values for heterogeneity are shown.


Supplemental figure 16: Forest plot of mean difference in LDL-cholesterol between white rice and brown rice groups in RCTs



Random-effects DerSimonian-Laird model

Mean difference in change from baseline (95% CI) of LDL-cholesterol (mmol/L) between brown rice and white rice (control) regimens from RCTs. Trials evaluated the effect of replacing white rice with brown rice. Horizontal lines denote 95% CIs; solid squares represent the point estimate of each study with the size proportional to study weight. Open diamonds represent pooled estimates from the random-effects model (DerSimonian-Laird) and fixed-effects model. Study weights are from the random-effects analysis. The I^2 and P values for heterogeneity are shown.


Supplemental figure 17: Forest plot of mean difference in fasting blood glucose (FBG) between white rice and brown rice groups in RCTs



Random-effects DerSimonian-Laird model


Mean difference in change from baseline (95% CI) of fasting blood glucose (FBG) (mmol/L) between brown rice and white rice (control) regimens from RCTs. Trials evaluated the effect of replacing white rice with brown rice. Horizontal lines denote 95% CIs; solid squares represent the point estimate of each study with the size proportional to study weight. Open diamonds represent pooled estimates from the random-effects model (DerSimonian-Laird) and fixed-effects model. Study weights are from the random-effects analysis. The I^2 and P values for heterogeneity are shown.

Supplemental figure 18: Forest plot of mean difference in waist circumference between white rice and brown rice groups in RCTs




Mean difference in change from baseline (95% CI) in waist circumference (cm) between brown rice and white rice (control) regimens from RCTs. Trials evaluated the effect of replacing white rice with brown rice. Horizontal lines denote 95% CIs; solid squares represent the point estimate of each study with the size proportional to study weight. Open diamonds represent pooled estimates from the random-effects model (DerSimonian-Laird) and fixed-effects model. Study weights are from the random-effects analysis. The I^2 and P values for heterogeneity are shown.

Supplemental figure 19: Influence analysis of individual prospective cohort studies in the meta-analysis of white rice intake and risk of T2D




Influence of individual cohorts on the pooled RR of white rice intake and risk of T2D. The squares with the horizontal lines represent the pooled RR and corresponding 95% CI with the removal of the individual cohorts. The vertical dashed lines indicate the lower 95% CI, overall pooled RR, and upper 95% CI (from left to right). M, male; F, female; MCC, Melbourne Collaborative Cohort Study; SWHS, Shanghai Women's Health Study; JPHC, Japan Public Health Center-based Prospective Study; HPFS, Health Professionals Follow-up Study; NHS, Nurses' Health Study; PS, Pizarra study; GCS, Golestan Cohort Study; TLGS, Tehran Lipid and Glucose Study; SCHS, Singapore Chinese Health Study; PURE, Prospective Urban Rural Epidemiology Study. Weights are from the random-effects model and represent the percent weight of the effect estimate after an individual study has been removed relative to the overall summary estimate.

Supplemental figure 20: Influence analysis of individual RCTs replacing white rice with brown rice in the meta-analysis of FBG




Influence of individual RCTs on the pooled estimate for fasting blood glucose (FBG). The squares with the horizontal lines represent the pooled estimate and corresponding 95% CI with the removal of the individual RCTs. The vertical dashed lines indicate the lower 95% CI, overall pooled estimate, and upper 95% CI (from left to right). Weights are from the random-effects model and represent the percent weight of the effect estimate after an individual study has been removed relative to the overall summary estimate.

Supplemental figure 21: Influence analysis of individual RCTs replacing white rice with brown rice in the meta-analysis of HDL cholesterol




Influence of individual RCTs on the pooled estimate for HDL cholesterol. The squares with the horizontal lines represent the pooled estimate and corresponding 95% CI with the removal of the individual RCTs. The vertical dashed lines indicate the lower 95% CI, overall pooled estimate, and upper 95% CI (from left to right). Weights are from the random-effects model and represent the percent weight of the effect estimate after an individual study has been removed relative to the overall summary estimate.

Supplemental figure 22: Influence analysis of individual RCTs replacing white rice with brown rice in the meta-analysis of LDL cholesterol




Influence of individual RCTs on the pooled estimate for LDL cholesterol. The squares with the horizontal lines represent the pooled estimate and corresponding 95% CI with the removal of the individual RCTs. The vertical dashed lines indicate the lower 95% CI, overall pooled estimate, and upper 95% CI (from left to right). Weights are from the random-effects model and represent the percent weight of the effect estimate after an individual study has been removed relative to the overall summary estimate.


Supplemental figure 23: Influence analysis of individual RCTs replacing white rice with brown rice in the meta-analysis of triglycerides




Influence of individual RCTs on the pooled estimate for triglycerides (TAG). The squares with the horizontal lines represent the pooled estimate and corresponding 95% CI with the removal of the individual RCTs. The vertical dashed lines indicate the lower 95% CI, overall pooled estimate, and upper 95% CI (from left to right). Weights are from the random-effects model and represent the percent weight of the effect estimate after an individual study has been removed relative to the overall summary estimate.

Supplemental figure 24: Funnel plot for meta-analysis of prospective cohort studies of white rice (WR) intake and risk of T2D


Funnel plot and corresponding Begg's and Egger's test for assessment of potential publication bias in meta-analysis of prospective cohort studies of white rice (WR) consumption and risk of T2D.

Supplemental figure 25: Funnel plot for meta-analysis of RCTs replacing white rice with brown rice for FBG


Funnel plot and corresponding Begg's and Egger's test for assessment of potential publication bias in meta-analysis of RCTs replacing white rice with brown rice for fasting blood glucose (FBG).

Supplemental figure 26: Funnel plot for meta-analysis of RCTs replacing white rice with brown rice for HDL cholesterol

Funnel plot and corresponding Begg's and Egger's test for assessment of potential publication bias in meta-analysis of RCTs replacing white rice with brown rice for HDL cholesterol.

Supplemental figure 27: Funnel plot for meta-analysis of RCTs replacing white rice with brown rice for LDL cholesterol

Funnel plot and corresponding Begg's and Egger's test for assessment of potential publication bias in meta-analysis of RCTs replacing white rice with brown rice for LDL cholesterol.

Supplemental figure 28: Funnel plot for meta-analysis of RCTs replacing white rice with brown rice for triglycerides

Funnel plot and corresponding Begg's and Egger's test for assessment of potential publication bias in meta-analysis of RCTs replacing white rice with brown rice for triglycerides (TG).



PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
TITLE			
Title	1	Identify the report as a systematic review.	Title
ABSTRACT			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	Abstract
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	Page 5
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	Page 5
METHODS			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	Page 6
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	Page 6
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	Supplemental Table 1
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	Page 7
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	Page 7/8
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	Page 7-8
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	Page 8-10
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	Page 9-10
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	Table 1, Table 1, Supplemental Table 2
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	Page 9-10
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	Page 9
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	Page 9-10
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	Page 8
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	Page 8
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	Page 8-9



PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	Page 10
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	Page 9-10
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	Page 10, figure 1
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	Page 10, figure 1
Study characteristics	17	Cite each included study and present its characteristics.	Page 11, Table 1, Table 2
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	Page 11-12 Table 1, Table 2
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	Page 12-12 Figure 2 Supplemental Figures 1-6 Figure 3 Table 3 Supplemental Figures 8-18
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	Page 12-15
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	Page 12-12 Figure 2 Supplemental Figures 1-6 Figure 3 Table 3 Supplemental Figures 8-18
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	Page 12-15
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	Page 12-15
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	Page 14
Certainty of	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	Page 15



PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
evidence			
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	Page 15-16
	23b	Discuss any limitations of the evidence included in the review.	Page 18-19
	23c	Discuss any limitations of the review processes used.	Page 19
	23d	Discuss implications of the results for practice, policy, and future research.	Page 19
OTHER INFORMATION			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	Page 6
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	Page 6
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	NA
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	Page 20
Competing interests	26	Declare any competing interests of review authors.	Page 20
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	Page 22

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71. doi: 10.1136/bmj.n71

For more information, visit: <http://www.prisma-statement.org/>